Perspective · 10 Sep 2026
Conference abstractPublished 29 Sep 2014
Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist maraviroc
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The CCR5 chemokine receptor is crucial for human immunodeficiency virus type 1 (HIV-1) infection, acting as the principal coreceptor for HIV-1 entry and transmission and is thus an attractive target for antiviral therapy. Studies have suggested that CCR5 surface density and its conformational changes subsequent to virion engagement are rate limiting for entry, and consequently, infection. Not all CCR5 antibodies reduce HIV-1 binding, entry and infection, suggesting a need for more potent reagents. Here full length single chain (FLSC) IgG1, a novel CD4-gp120BAL fusion protein with several characteristics was evaluated that makes it an attractive candidate for treatment of HIV-1 infections, including bivalency and a potentially increased serum half-life over FLSC itself. FLSC IgG1 binds two domains on CCR5, the N-terminus and the second extracellular loop, lowering the levels of available CCR5 viral attachment sites. Furthermore, FLSC IgG1 is synergistic with Maraviroc, the only one licensed CCR5 antagonist. In this study, both, microscopy and functional assays were used to address the mechanistic aspects of the interactions of FLSC IgG1 and Maraviroc in the context of CCR5 conformational changes and viral infection. A novel Stochastic Optical Reconstruction Microscopy (STORM) was used based on high-accuracy of photoswitchable dyes localization with high resolution to visualize direct contacts between FLSC IgG1 and CCR. Viral entry inhibition by FLSC IgG1 with that of other CCR5 blockers was compared and showed FLSC IgG1 to be the most potent. Also it was also shown that lower CCR5 surface densities in HIV-1 infected primary cells result in reduced FLSC IgG1 EC50 values. In addition, CCR5 binding by the FLSC IgG1, but not by 2D7, was significantly increased when cells were treated with MVC, suggesting MVC increases exposure of the relevant epitope. Together, this data may have implications on future anti-viral therapy efforts
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Olga Latinovic”
- BylineArticles whose byline prints “Kate Schneider”
- BylineArticles whose byline prints “Henryk Szmacinski”
- BylineArticles whose byline prints “Joseph Lakowicz”
- BylineArticles whose byline prints “Alonso Heredia”
- BylineArticles whose byline prints “Robert R Redfield”
